Clinical Pharmacology of Doxacurium Chloride (BW A938U) in Children

Jb, Sarner; Bw, Brandom; Dr, Cook; Dong, Mei; Mc, Horn; Sk, Woelfel; Pj, Davis; Gd, Rudd; Vj, Foster; Bf, McNulty

doi:10.1213/00000539-198804000-00001

Cited by 30 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They identified the sensitivity of infants to nondepolarizing neuromuscular blockers 12 and the relative resistance to children (larger ED 95 ) when compared to adults. 7,13 The ED 95 of doxacurium was measured in children 2-10 years old and was larger than the historically recorded ED 95 in adults administered similar anesthetic agents. 13 They also identified a similar relationship between age and vecuronium infusion rates.…”

Section: During Dr Cook's Third Year Of Medical School He Was Hired mentioning

confidence: 86%

“…7,13 The ED 95 of doxacurium was measured in children 2-10 years old and was larger than the historically recorded ED 95 in adults administered similar anesthetic agents. 13 They also identified a similar relationship between age and vecuronium infusion rates. Children between the ages of two and 10 required a larger infusion rate than different adult age groups during a narcotic-nitrous anesthetic.…”

Section: During Dr Cook's Third Year Of Medical School He Was Hired mentioning

confidence: 86%

“…Dr Cook and his research team, comprising Drs. Barbara Brandom, Susan Woelfel, Peter Davis, and Richard Stiller, went on to investigate the pharmacology of nondepolarizing neuromuscular blockers including vecuronium, mivacurium, atracurium, and doxacurium . They helped define the dose response, duration, pharmacokinetics, and clinical side effects of these agents in neonates, infants, and children.…”

Section: Era Of Clinical Pharmacologymentioning

confidence: 99%

“…They helped define the dose response, duration, pharmacokinetics, and clinical side effects of these agents in neonates, infants, and children. They identified the sensitivity of infants to nondepolarizing neuromuscular blockers and the relative resistance to children (larger ED 95 ) when compared to adults . The ED 95 of doxacurium was measured in children 2‐10 years old and was larger than the historically recorded ED 95 in adults administered similar anesthetic agents .…”

Section: Era Of Clinical Pharmacologymentioning

confidence: 99%

“…18 4 Defined the pharmacokinetic and pharmacodynamics effects of volatile anesthetics in pediatric patients. 30 6,7,[11][12][13] They helped define the dose response, duration, pharmacokinetics, and clinical side effects of these agents in neonates, infants, and children. They identified the sensitivity of infants to nondepolarizing neuromuscular blockers 12 and the relative resistance to children (larger ED 95 ) when compared to adults.…”

Section: During Dr Cook's Third Year Of Medical School He Was Hired mentioning

confidence: 99%

See 4 more Smart Citations

The advancement of pediatric anesthesia pharmacology: David Ryan Cook (scions, serendipity, and six degrees of separation)

Cladis

Christine

Yaster

et al. 2018

Pediatric Anesthesia

Self Cite

View full text Add to dashboard Cite

Summary Dr David Ryan Cook, Professor Emeritus of Anesthesiology and Pharmacology at the University of Pittsburgh and Chief of Anesthesiology at Children's Hospital of Pittsburgh (1977‐1999), is a pioneer in the field of pediatric anesthesiology and pharmacology. Dr Cook contributed significantly to the understanding of pharmacologic differences among infants, children, and adults. His work as a clinician‐scientist, educator, and mentor defined the pharmacology of many of the anesthetic agents we continue to use today. He brought science to the art of anesthesia and enhanced the safety of pediatric perioperative care. Based on a 2017 interview with Dr Cook, this article outlines the development of his career and his contributions to the field of anesthesiology and pharmacology.

show abstract